Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

ranibizumab

ranibizumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Lucentis SOLUTION, INTRAOCULAR 10 mg/mL    
Cimerli SOLUTION, INTRAVITREAL 0.3 mg, 0.5 mg    
Byooviz SOLUTION, INTRAVITREAL 0.5 mg    
Comments:

Lucentis & Byooviz doses ordered for macular degeneration should be interchanged to Avastin.

Lucentis, Byooviz, & Cimerli are classified as therapeutically equivalent for the FDA approved indications. The most cost-effective product may be utilized.

Lucentis is formulary restricted to retina surgeons for treatment of retinopathy of prematurity.

 

 

Reviewed: October 25, 2006 (Lucentis), July 2024 (Byooviz), October 2024 (Cimerli)

Updated: 23 April 2019 (Lucentis)

Ranibizumab eqrn (CIMERLI) Spotlight - Copy.pdf

Ranibizumab-nuna (BYOOVIZ) Comparison

Last updated: Dec. 24, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved